BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

被引：0
作者：
A. S. Hamy
I. Bieche
J. Lehmann-Che
V. Scott
Ph. Bertheau
J. M. Guinebretière
M. C. Matthieu
B. Sigal-Zafrani
O. Tembo
M. Marty
B. Asselain
F. Spyratos
P. de Cremoux
机构：
[1] Institut Curie,Department of Biostatistics
[2] Institut Curie,Pharmacogenomics Unit, Department of Genetics
[3] Paris Diderot University,APHP Molecular Oncology Unit, Hôpital Saint Louis
[4] Institut Gustave Roussy,Biology Department
[5] Paris Diderot University,APHP Pathology Department, Hôpital Saint Louis
[6] Institut Curie,Pathology Department, Hôpital René
[7] Institut Gustave Roussy,Huguenin
[8] Institut Curie,Pathology Department
[9] Saint-Louis Hospital,Pathology Department
来源：
Breast Cancer Research and Treatment | 2016年 / 159卷
关键词：
Breast cancer; Neoadjuvant chemotherapy; Predictive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：499 / 511
页数：12
相关论文
共 50 条
[31]   Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma [J].
Kuerer, HM ;
Singletary, SE ;
Buzdar, AU ;
Ames, FC ;
Valero, V ;
Buchholz, TA ;
Ross, MI ;
Pusztai, L ;
Hortobagyi, GN ;
Hunt, KK .
AMERICAN JOURNAL OF SURGERY, 2001, 182 (06) :601-608
[32]   MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer [J].
Laura Esserman ;
Elizabeth Kaplan ;
Savanah Partridge ;
Debasish Tripathy ;
Hope Rugo ;
John Park ;
Shelley Hwang ;
Henry Kuerer ;
Dan Sudilovsky ;
Ying Lu ;
Nola Hylton .
Annals of Surgical Oncology, 2001, 8 (6) :549-559
[33]   Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer [J].
Liu, Baoquan ;
Su, Fei ;
Li, Yue ;
Qi, Xiuying ;
Liu, Xiangchen ;
Liang, Wenlong ;
You, Kai ;
Zhang, Yafang ;
Zhang, Jianguo .
BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 :911-917
[34]   MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer [J].
Esserman, L ;
Kaplan, E ;
Partridge, S ;
Tripathy, D ;
Rugo, H ;
Park, J ;
Hwang, S ;
Kuerer, H ;
Sudilovsky, D ;
Lu, Y ;
Hylton, N .
ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (06) :549-559
[35]   Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer [J].
Bhumsuk Keam ;
Seock-Ah Im ;
Hee-Jun Kim ;
Do-Youn Oh ;
Jee Hyun Kim ;
Se-Hoon Lee ;
Eui Kyu Chie ;
Wonshik Han ;
Dong-Wan Kim ;
Woo Kyung Moon ;
Tae-You Kim ;
In Ae Park ;
Dong-Young Noh ;
Dae Seog Heo ;
Sung Whan Ha ;
Yung-Jue Bang .
BMC Cancer, 7
[36]   FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients [J].
Caroline Rousseau ;
Anne Devillers ;
Mario Campone ;
Loïc Campion ;
Ludovic Ferrer ;
Christine Sagan ;
Myriam Ricaud ;
Boumédiène Bridji ;
Françoise Kraeber-Bodéré .
European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 :1029-1036
[37]   FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients [J].
Rousseau, Caroline ;
Devillers, Anne ;
Campone, Mario ;
Campion, Loic ;
Ferrer, Ludovic ;
Sagan, Christine ;
Ricaud, Myriam ;
Bridji, Boumediene ;
Kraeber-Bodere, Francoise .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (06) :1029-1036
[38]   The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer [J].
Beresford, M. J. ;
Harris, A. L. ;
Ah-See, M. ;
Daley, F. ;
Padhani, A. R. ;
Makris, A. .
BRITISH JOURNAL OF CANCER, 2006, 95 (12) :1683-1688
[39]   The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer [J].
M J Beresford ;
A L Harris ;
M Ah-See ;
F Daley ;
A R Padhani ;
A Makris .
British Journal of Cancer, 2006, 95 :1683-1688
[40]   Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer [J].
Liu, Baoquan ;
Su, Fei ;
Chen, Mingwei ;
Li, Yue ;
Qi, Xiuying ;
Xiao, Jianbing ;
Li, Xuemei ;
Liu, Xiangchen ;
Liang, Wentong ;
Zhang, Yafang ;
Zhang, Jianguo .
HUMAN PATHOLOGY, 2017, 64 :44-52
12345